# Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults

> **NCT00397943** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 110 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** GSK's candidate Mycobacterium tuberculosis vaccine 692342
- **BIOLOGICAL:** Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system
- **BIOLOGICAL:** Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline
- **BIOLOGICAL:** Control vaccine with the adjuvant system.

## Key facts

- **NCT ID:** NCT00397943
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-15
- **Primary completion:** 2009-12-01
- **Final completion:** 2009-12-01
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2019-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00397943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00397943, "Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00397943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*